en · de · es
thymosin-alpha-1-notes.peptides1126.com › Wiki › Molecular Identity Of Thymosin Alpha-1 — 2026 Update

Molecular Identity Of Thymosin Alpha-1 — 2026 Update

By Editorial Desk · published 2026-04-20 · last reviewed 2026-05-17 · Wiki

The short version of prothymosin alpha fits in a sentence. The long version — which is the one that helps — is below.

Reviewed 2026-05-17. Anything still debated is marked as such rather than presented as settled.

Molecular Identity Of Thymosin Alpha-1

Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.

Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.

Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.

Analytical Methods and Storage Stability

The lyophilized peptide is generally stable for extended periods when kept cold and dry. Once dissolved, aqueous solutions are less stable; hydrolysis, oxidation, and aggregation can degrade the material. Storage at -20 °C or lower slows these processes. Repeated freeze-thaw cycles are best avoided because they can promote aggregation. The exact shelf life depends on formulation, pH, and concentration, so stability studies are typically performed for each specific product.

Quality control for thymosin alpha-1 focuses on identity, purity, and potency. Identity is confirmed by mass spectrometry and amino acid analysis, while purity is assessed by chromatography with limits on related substances and residual solvents. Potency assays may use cell-based immune readouts, but these are not standardized across laboratories. Regulatory status differs by jurisdiction; no product is approved in the United States for clinical use, whereas some other countries register injectable forms for specific indications.

Thymosin-alpha-1 at a glance

PropertyValueNotes
ClassSynthetic peptide28 residues; not a small-molecule compound
Molecular massAbout 3,106 DaMonoisotopic mass of the unmodified chain
N-terminal groupAcetylated serinePresent in both native and synthetic forms
Secondary structureDisulfide-constrained loopOne bridge between two cysteine residues
Typical sourceSolid-phase synthesisEarly isolates came from bovine thymus extracts

Molecular Background and Immune Action

Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.

Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.

Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.

Related pages on this site

Background and Biological Role

Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.

The activity of this peptide is generally described as immunomodulatory rather than directly antimicrobial. Experimental work links it to signaling through certain Toll-like receptors on dendritic cells and to downstream maturation of antigen-presenting cells. Reported effects include expansion of T cell subsets, shifts in cytokine profiles, and increased natural killer cell activity. These observations come largely from cell culture and animal models, and the precise receptor-level events in humans remain incompletely characterized.

Molecular Background and Identity

Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.

Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.

Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.

Notes from published material

After Runciter disappears, Jory reveals himself to Chip, telling him that he, not Conley, has now killed off the entire group (including Conley), as he "eats" half-lifers to sustain himself, and that the entire reality they are experiencing is created and maintained by him. Fortunately, Chip is temporarily protected from being consumed through the effect of Ubik, and leaves Jory. As he at last begins to deteriorate again, he meets Ella, who saves him by granting him a certificate for a life-long supply of Ubik, and instructs him to stay half-alive and seek cans of Ubik to further assist Runciter after she herself reincarnates. She states that Jory's family pays the facility to keep his body near other half-lifers for him to consume in order to prolong his own half-life, and that entities like Jory can arise in any collection of half-lifers. Ubik is claimed to have been developed by Ella and several other half-lifers as a defense against Jory. Each chapter is introduced by a commercial advertising Ubik as a different product serving a specific use. The last chapter is introduced by Ubik claiming that it has created and directed the universe, and that its real name is unknown and unspoken. In this short chapter, Runciter, who is in the "living" world mourning the loss of his best employees, discovers coins showing Chip's face, and feels that this is "just the beginning".

Three studies report specifications and results of the largest cosmological simulations that incorporate both dark matter and normal matter, further deepening the S8 tension challenge to the standard cosmological model.

The Ghana Stock Exchange is the fifth largest on continental Africa and third largest in sub-Saharan Africa, having a market capitalisation of GH¢ 57.2 billion or CN¥180.4 billion in 2012, with the South Africa JSE Limited ranked first. The Ghana Stock Exchange was the second best performing stock exchange in Sub-Saharan Africa in 2013. Ghana produces cocoa. It is the second largest producer of cocoa globally and its ICCO membership helps in its international cocoa trade. Ghana is classified as a middle-income country. Services account for 50% of GDP, followed by manufacturing (24.1%), extractive industries (5%), and taxes (20.9%). Ghana's economy is characterized by a growing manufacturing sector and the export of digital technology products. The country is also engaged in the assembly and export of automobiles and ships. Ghana's economy benefits from a range of resource-rich exports, including industrial minerals and agricultural products, with cocoa being a primary commodity. The nation is a producer and exporter of petroleum and natural gas. The information and communications technology (ICT) sector plays a role in Ghana's industrial landscape, with companies such as Rlg Communications, a state-affiliated digital technology corporation, leading in the production of tablet computers, smartphones, and consumer electronics. Urban electric cars have been manufactured in Ghana since 2014. Ghana announced plans to issue government debt by way of social and green bonds in autumn of 2021, making it the first African country to do so.

== Life support == The purpose of cardiopulmonary resuscitation (CPR) during cardiac arrest is ideally reversal of the clinically dead state by restoration of blood circulation and breathing. However, there is great variation in the effectiveness of CPR for this purpose. Blood pressure is very low during manual CPR, resulting in only a ten-minute average extension of survival. Yet there are cases of patients regaining consciousness during CPR while still in full cardiac arrest. In absence of cerebral function monitoring or frank return to consciousness, the neurological status of patients undergoing CPR is intrinsically uncertain. It is somewhere between the state of clinical death and a normal functioning state. Patients supported by methods that certainly maintain enough blood circulation and oxygenation for sustaining life during stopped heartbeat and breathing, such as cardiopulmonary bypass, are not customarily considered clinically dead. All parts of the body except the heart and lungs continue to function normally. Clinical death occurs only if machines providing sole circulatory support are turned off, leaving the patient in a state of stopped blood circulation.

Sources: en.wikipedia.org

Further detail

Abnormal facial characteristics, consisting of pronounced eyes which are spaced far apart (hypertelorism), a high forehead, a compressed bridge of the nose or saddle nose, and a small lower jaw and chin (micrognathia), are also observed in the majority of cases. Those affected by PD can also suffer intellectual disabilities (approx. 75% of recorded cases do) ranging from mild to severe – mental development during childhood may therefore progress more slowly.

Antagonism of the α1-adrenergic receptor is thought to cause orthostatic hypotension and dizziness. Inhibition of muscarinic acetylcholine receptors is responsible for the anticholinergic side effects of clomipramine like dry mouth, constipation, urinary retention, blurred vision, and cognitive/memory impairment. In overdose, sodium channel blockade in the brain is believed to cause the coma and seizures associated with TCAs while blockade of sodium channels in the heart is considered to cause cardiac arrhythmias, cardiac arrest, and death. On the other hand, sodium channel blockade is also thought to contribute to the analgesic effects of TCAs, for instance in the treatment of neuropathic pain. The exceptionally strong serotonin reuptake inhibition of clomipramine likely precludes the possibility of its antagonism of serotonin receptors (which it binds to with more than 100-fold lower affinity than the SERT) resulting in a net decrease in signaling by these receptors. In accordance, while serotonin receptor antagonists like cyproheptadine and chlorpromazine are effective as antidotes against serotonin syndrome, clomipramine is nonetheless capable of inducing this syndrome. In fact, while all TCAs are SRIs and serotonin receptor antagonists to varying extents, the only TCAs that are associated with serotonin syndrome are clomipramine and to a lesser extent its dechlorinated analogue imipramine, which are the two most potent SRIs of the TCAs (and in relation to this have the highest ratios of serotonin reuptake inhibition to serotonin receptor antagonism).

=== Urodeles === Salamanders, including newts and axolotls, are species with the most known regenerative abilities. Adult newts can regenerate limbs, tail, upper and lower jaws, spinal cord, retinas, lenses, optic nerves, intestine, and a portion of its heart ventricle Axolotls share the same abilities, save the retina and lens. These animals are important to the study of dedifferentiation because they use dedifferentiation to create new progenitor cells. This is different from mammalian regeneration, because mammals use preexisting stem cells to replace lost tissues. Dedifferentiation in the newt occurs 4–5 days after limb amputation and is characterized by cell cycle re-entry and down-regulation of differentiation markers. cell differentiation is determined by what genes the cell expresses, and down-regulation of this expression would make for a less, or “un”, differentiated cell. Re-entry into the cell cycle allows the cell to go through mitosis, dividing to make more cells that would be able to provide new tissue. It has been observed that actinomycin D prevents dedifferentiation in newts

== Prevention == Many types of dwarfism are currently impossible to prevent because they are genetically caused. Genetic conditions that cause dwarfism may be identified with genetic testing, by screening for the specific variations that result in the condition. However, due to the number of causes of dwarfism, it may be impossible to determine definitively if a child will be born with dwarfism. Dwarfism resulting from malnutrition or a hormonal abnormality may be treated with an appropriate diet or hormonal therapy. Growth hormone deficiency may be remedied via injections of human growth hormone during childhood.

In the Earth's magnetic field, NMR frequencies are in the audio frequency range, or the very low frequency and ultra low frequency bands of the radio frequency spectrum. Earth's field NMR (EFNMR) is typically stimulated by applying a relatively strong dc magnetic field pulse to the sample and, after the end of the pulse, analyzing the resulting low frequency alternating magnetic field that occurs in the Earth's magnetic field due to free induction decay (FID). These effects are exploited in some types of magnetometers, EFNMR spectrometers, and MRI imagers. Their inexpensive portable nature makes these instruments valuable for field use and for teaching the principles of NMR and MRI. An important feature of EFNMR spectrometry compared with high-field NMR is that some aspects of molecular structure can be observed more clearly at low fields and low frequencies, whereas other aspects observable at high fields are not observable at low fields. This is because:

Sources: en.wikipedia.org

Supporting material

== Toxicological data == The toxicological effects of 2,6‑dichloro‑1,4‑benzoquinone (2,6‑DCBQ) have been investigated in several experimental models. In mice, a 28‑day exposure study reported renal injury following 2,6‑DCBQ exposure. Proposed mechanisms include the activation of inflammatory pathways, oxidative stress, and apoptosis. Toxicity has also been examined in embryonic zebrafish, where exposure resulted in acute and developmental toxicity. Observed effects included impaired cardiovascular development and alterations in molecular signaling pathways. Studies using human cell lines have also reported cytotoxic effects. In kidney cells, exposure primarily induces anoikis, a form of apoptosis associated with loss of cell–matrix interactions. In human colon epithelial and liver cells, 2,6‑DCBQ exposure increases the production of reactive oxygen species (ROS). Prolonged low‑dose exposure in normal colon and liver cell lines has been associated with oxidative stress, DNA damage, and molecular changes that may indicate a potential role in carcinogenesis. In cell culture systems, the half‑life of 2,6‑DCBQ has been estimated to be less than one hour, and the parent compound appears to exhibit greater cytotoxicity than its transformation product.

Etacrynic acid (INN) or ethacrynic acid (USAN), trade name Edecrin, is a loop diuretic used to treat high blood pressure and the swelling caused by diseases like congestive heart failure, liver failure, and kidney failure. A disadvantage with ethacrynic acid, compared to the other loop diuretic drugs such as furosemide, is that it has a significantly steep dose-response curve. This means the drug's dosing is very important as small variance in dose can cause a significant difference in the biological response. Unlike the other loop diuretics, etacrynic acid is not a sulfonamide and may thus be used in individuals with sulfa allergies in whom the sulfonamide loop diuretics would be contraindicated.

Plants are not passive, but respond to external signals such as light, touch, and injury by moving or growing towards or away from the stimulus, as appropriate. Tangible evidence of touch sensitivity is the almost instantaneous collapse of leaflets of Mimosa pudica, the insect traps of Venus flytrap and bladderworts, and the pollinia of orchids. The hypothesis that plant growth and development is coordinated by plant hormones or plant growth regulators first emerged in the late 19th century. Darwin experimented on the movements of plant shoots and roots towards light and gravity, and concluded "It is hardly an exaggeration to say that the tip of the radicle…acts like the brain of one of the lower animals…directing the several movements." About the same time, the role of auxins (from the Greek auxein, to grow) in control of plant growth was first outlined by the Dutch scientist Frits Went. The first known auxin, indole-3-acetic acid (IAA), which promotes cell growth, was only isolated from plants about 50 years later. This compound mediates the tropic responses of shoots and roots towards light and gravity. The finding in 1939 that plant callus could be maintained in culture containing IAA, followed by the observation in 1947 that it could be induced to form roots and shoots by controlling the concentration of growth hormones were key steps in the development of plant biotechnology and genetic modification.

== Discovery == Motilin was discovered by J.C. Brown when he introduced alkaline solution into duodena of dogs, which caused strong gastric contractions. Brown et al. predicted that alkali could either release stimulus to activate motor activity or prevent the secretion of inhibitory hormone. They isolated a polypeptide as a by-product from purification of secretin on carboxymethyl cellulose. They named this polypeptide "Motilin."

== Reaction similarity == Similarity between enzymatic reactions (EC) can be calculated by using bond changes, reaction centres or substructure metrics (EC-BLAST Archived 30 May 2019 at the Wayback Machine).

Sources: en.wikipedia.org

Frequently asked questions

Is this peptide found naturally in the body?

Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.

Why is the disulfide bridge important?

The single bridge between two cysteine residues holds the chain in a folded loop that influences its shape and its behavior in solution. Loss of the bridge through reduction or oxidation shifts chromatographic retention and is tracked during stability work.

How does it differ from other thymic peptides?

It is a defined 28-residue sequence derived from a larger precursor, whereas many other thymic preparations are mixtures of several polypeptides. Its acetylated amino terminus and single disulfide bridge distinguish it chemically from unrelated thymic extracts.

How is thymosin alpha-1 measured in a laboratory?

Reverse-phase HPLC with ultraviolet detection at 214 nm is common. Mass spectrometry is used to confirm molecular identity and detect modifications. Immunoassays exist but may not distinguish the intact peptide from fragments.

Network